LEHI, Utah, Feb. 24, 2025 /PRNewswire/ — CivicaScript,® a nonprofit company dedicated to bringing low-cost generic medicines to U.S. consumers, announced today that it has lowered the price of its ...

Lower-dose abiraterone demonstrated comparable efficacy to standard-dose abiraterone in select men with mCRPC. Lower-dose abiraterone acetate, 250 mg with low-fat food, is similarly effective to the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

Data for 1,410 abiraterone-treated patients from 2011 to 2022 were identified from a large academic/community hospital system. Three hundred and fifty-three patients were excluded for missing ...

Please provide your email address to receive an email when new articles are posted on . Men treated with enzalutamide lived about a month longer than those who received abiraterone acetate. Men who ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

The Institute of Cancer Research, London, has broadly welcomed the approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate ...

The Institute of Cancer Research, London, has expressed disappointment at the decision by NICE not to recommend abiraterone as a first-line treatment on the NHS for newly diagnosed, advanced prostate ...

Enzalutamide may offer a survival advantage compared with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC), according to 2 US studies of older men. Overall survival ...